GSK plc ADR Stock
Price
Target price
€38.20
€38.20
0.530%
0.2
0.530%
€49.33
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
GSK plc ADR Stock
GSK plc ADR gained 0.530% compared to yesterday.
GSK plc ADR is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
As a result the target price of 49 € shows a positive potential of 28.27% compared to the current price of 38.2 € for GSK plc ADR.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for GSK plc ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of GSK plc ADR in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of GSK plc ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| GSK plc ADR | 0.530% | 1.596% | 5.525% | 18.634% | 13.690% | -13.672% | -16.957% |
| Astrazeneca ADR | 0.000% | 0.649% | 6.164% | 21.094% | 26.016% | 54.382% | - |
| Bayer AG ADR | 3.700% | -2.098% | 6.061% | -43.548% | -18.605% | -40.678% | -58.084% |
| Novo Nordisk A/S ADR | -1.210% | 0.000% | -0.407% | -30.000% | 30.597% | 35.809% | 160.638% |
Comments
GSK plc (NYSE: GSK) had its price target raised by analysts at Jefferies Financial Group Inc. from $52.50 to $53.00. They now have a "buy" rating on the stock.
Show more
Ratings data for GSK provided by MarketBeat
GSK plc (NYSE: GSK) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Show more
Ratings data for GSK provided by MarketBeat
GSK plc (NYSE: GSK) was upgraded by analysts at Berenberg Bank to a "strong-buy" rating.
Show more
Ratings data for GSK provided by MarketBeat
News
Is GSK a Top Value Stock Right Now?
GSK (NYSE: GSK), a global healthcare powerhouse, has been on a transformative journey since CEO Emma Walmsley took the helm in 2017. Despite its shares badly underperforming the S&P 500 under her
Positive News is Driving This Cancer Drug Maker’s Stock Higher
Shares of IDEAYA Biosciences Inc. (NASDAQ: IDYA) are up more than 16% after announcing positive treatment data for its Phase 2 clinical trial. The company’s pipeline candidate, IDE397, is an
